GenArraytion had been structured around provision of products and services for medical diagnostics, biodefense and environmental monitoring. The firm's large library of molecular signatures could be used for high confidence pathogen identification and determination of virulence mechanisms and antibiotic susceptibility in a single test. The increasing frequency and severity of diseases resulting from pathogens with resistance to multiple antibiotics such as MRSA have created an urgent need for improved diagnostic methods. GenArraytion's high fidelity pathogen assays identify infectious disease agents and their antibiotic susceptibility in a fraction of the time required with current methods. In July 2021, it was announced that publicly traded Nephros, Inc. (Nasdaq: NEPH) - a water technology company providing filtration and pathogen detection solutions to the medical and commercial markets - had acquired substantially all of the assets of Rockville, MD-based GenArraytion, Inc - a small firm with expertise in infectious disease monitoring and measurement: proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms using Polymerase Chain Reaction (PCR) technology.
